Home › Companies › ALNYLAM PHARMACEUTICALS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ALNYLAM PHARMACEUTICALS INC.’s Form 8-K, filed May 20, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 16, 2024: 6 items on ALNYLAM PHARMACEUTICALS INC.’s Form 8-K, filed May 20, 2024: 4 elected · 2 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore ALNYLAM PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are ALNYLAM PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dennis A. Ausiello, M.D. | 103,971,532 | 8,960,235 | 14,285 | -- | 4,991,057 | 92% | Elected | — |
| Elect Director: Olivier Brandicourt, M.D. | 106,444,201 | 6,487,472 | 14,379 | -- | 4,991,057 | 94% | Elected | — |
| Elect Director: Peter N. Kellogg | 108,577,015 | 4,354,577 | 14,460 | -- | 4,991,057 | 96% | Elected | — |
| Elect Director: David E.I. Pyott | 102,273,209 | 10,658,278 | 14,565 | -- | 4,991,057 | 91% | Elected | — |
| 2. Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers. The voting | 106,783,262 | 6,133,628 | 29,162 | -- | 4,991,057 | 95% | Approved | — |
| 3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2024 | 114,460,115 | 3,456,326 | 20,668 | -- | 0 | 97% | Approved | — |
This meeting is also recorded here as May 17, 2024; both records come from the same filing, so the date should be checked against it.
Source: ALNYLAM PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 20, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
503 asset managers disclosed a vote on at least one ALNYLAM PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees as Class II directors of Alnylam: David E.I. Pyott
ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David E.I. Pyott”): 102,273,209 for, 10,658,278 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 60,356,958 for, 5,409,246 against, 6,114 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 18,597,294 | 0 | 0 | 0 | For |
| Capital Group | 14,436,051 | 0 | 0 | 0 | For |
| Fidelity | 9,412,385 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 4,521,656 | 0 | 0 | Against |
| BlackRock | 3,341,538 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,331,971 | 0 | 0 | 0 | For |
| Dodge & Cox | 2,854,341 | 0 | 0 | 0 | For |
| American Century | 1,028,316 | 0 | 0 | 0 | For |
| JPMorgan | 1,000,946 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 888,487 | 0 | 0 | 0 | For |
| State Street | 571,157 | 130 | 0 | 0 | For |
| Jackson National | 306,432 | 251,010 | 0 | 0 | Mixed |
| TIAA | 539,348 | 0 | 0 | 0 | For |
| Charles Schwab | 442,624 | 0 | 0 | 0 | For |
| Equitable | 172,037 | 51,639 | 0 | 0 | Mixed |
| First Trust | 219,863 | 0 | 0 | 0 | For |
| BNY Mellon | 206,703 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 194,004 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 192,539 | 0 | 0 | 0 | For |
| MassMutual | 1,795 | 187,332 | 0 | 0 | Against |
| Aberdeen | 174,015 | 0 | 0 | 0 | For |
| John Hancock | 124,098 | 49,226 | 0 | 0 | Mixed |
| FRANKLIN STRATEGIC SERIES | 148,400 | 0 | 0 | 0 | For |
| Federated Hermes | 147,700 | 0 | 0 | 0 | For |
| Dimensional | 136,870 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees as Class II directors of Alnylam: Dennis A. Ausiello, M.D.
ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dennis A. Ausiello, M.D.”): 103,971,532 for, 8,960,235 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 60,426,871 for, 5,339,333 against, 6,114 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 18,597,294 | 0 | 0 | 0 | For |
| Capital Group | 14,436,051 | 0 | 0 | 0 | For |
| Fidelity | 9,412,385 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 4,521,656 | 0 | 0 | Against |
| BlackRock | 3,341,538 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,331,971 | 0 | 0 | 0 | For |
| Dodge & Cox | 2,854,341 | 0 | 0 | 0 | For |
| American Century | 1,028,316 | 0 | 0 | 0 | For |
| JPMorgan | 1,000,946 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 888,487 | 0 | 0 | 0 | For |
| State Street | 571,074 | 213 | 0 | 0 | For |
| Jackson National | 306,432 | 251,010 | 0 | 0 | Mixed |
| TIAA | 539,348 | 0 | 0 | 0 | For |
| Charles Schwab | 442,624 | 0 | 0 | 0 | For |
| Equitable | 172,037 | 51,639 | 0 | 0 | Mixed |
| First Trust | 219,863 | 0 | 0 | 0 | For |
| BNY Mellon | 206,703 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 194,004 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 192,539 | 0 | 0 | 0 | For |
| MassMutual | 1,795 | 187,332 | 0 | 0 | Against |
| Aberdeen | 174,015 | 0 | 0 | 0 | For |
| John Hancock | 124,098 | 49,226 | 0 | 0 | Mixed |
| FRANKLIN STRATEGIC SERIES | 148,400 | 0 | 0 | 0 | For |
| Federated Hermes | 147,700 | 0 | 0 | 0 | For |
| Dimensional | 136,870 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees as Class II directors of Alnylam: Olivier Brandicourt, M.D.
ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Olivier Brandicourt, M.D.”): 106,444,201 for, 6,487,472 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 62,548,914 for, 3,217,290 against, 6,114 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 18,597,294 | 0 | 0 | 0 | For |
| Capital Group | 14,436,051 | 0 | 0 | 0 | For |
| Fidelity | 9,412,385 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,664,187 | 2,857,469 | 0 | 0 | Mixed |
| BlackRock | 3,341,538 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,331,971 | 0 | 0 | 0 | For |
| Dodge & Cox | 2,854,341 | 0 | 0 | 0 | For |
| American Century | 1,028,316 | 0 | 0 | 0 | For |
| JPMorgan | 1,000,946 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 888,487 | 0 | 0 | 0 | For |
| State Street | 571,225 | 62 | 0 | 0 | For |
| Jackson National | 557,442 | 0 | 0 | 0 | For |
| TIAA | 539,348 | 0 | 0 | 0 | For |
| Charles Schwab | 442,624 | 0 | 0 | 0 | For |
| Equitable | 172,037 | 51,639 | 0 | 0 | Mixed |
| First Trust | 219,863 | 0 | 0 | 0 | For |
| BNY Mellon | 14,353 | 192,350 | 0 | 0 | Mixed |
| OLD WESTBURY FUNDS INC | 194,004 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 192,539 | 0 | 0 | 0 | For |
| MassMutual | 189,127 | 0 | 0 | 0 | For |
| Aberdeen | 174,015 | 0 | 0 | 0 | For |
| John Hancock | 124,098 | 49,226 | 0 | 0 | Mixed |
| FRANKLIN STRATEGIC SERIES | 148,400 | 0 | 0 | 0 | For |
| Federated Hermes | 147,700 | 0 | 0 | 0 | For |
| Dimensional | 136,870 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees as Class II directors of Alnylam: Peter N. Kellogg
ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Peter N. Kellogg”): 108,577,015 for, 4,354,577 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 62,773,501 for, 2,992,703 against, 6,114 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 18,597,294 | 0 | 0 | 0 | For |
| Capital Group | 14,436,051 | 0 | 0 | 0 | For |
| Fidelity | 9,412,385 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,664,187 | 2,857,469 | 0 | 0 | Mixed |
| BlackRock | 3,341,538 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,331,971 | 0 | 0 | 0 | For |
| Dodge & Cox | 2,854,341 | 0 | 0 | 0 | For |
| American Century | 1,028,316 | 0 | 0 | 0 | For |
| JPMorgan | 1,000,946 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 888,487 | 0 | 0 | 0 | For |
| State Street | 571,225 | 62 | 0 | 0 | For |
| Jackson National | 557,442 | 0 | 0 | 0 | For |
| TIAA | 539,348 | 0 | 0 | 0 | For |
| Charles Schwab | 442,624 | 0 | 0 | 0 | For |
| Equitable | 172,037 | 51,639 | 0 | 0 | Mixed |
| First Trust | 219,863 | 0 | 0 | 0 | For |
| BNY Mellon | 206,703 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 194,004 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 192,539 | 0 | 0 | 0 | For |
| MassMutual | 189,127 | 0 | 0 | 0 | For |
| Aberdeen | 174,015 | 0 | 0 | 0 | For |
| John Hancock | 124,098 | 49,226 | 0 | 0 | Mixed |
| FRANKLIN STRATEGIC SERIES | 148,400 | 0 | 0 | 0 | For |
| Federated Hermes | 147,700 | 0 | 0 | 0 | For |
| Dimensional | 136,870 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 23 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.
ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“2. The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers. The voting”): 106,783,262 for, 6,133,628 against — passed, per its Form 8-K filed May 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 18,597,294 | 0 | 0 | 0 | For |
| Capital Group | 14,436,051 | 0 | 0 | 0 | For |
| Fidelity | 9,412,385 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,464,575 | 57,081 | 0 | 0 | For |
| BlackRock | 3,341,538 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,331,971 | 0 | 0 | 0 | For |
| Dodge & Cox | 2,854,341 | 0 | 0 | 0 | For |
| American Century | 0 | 1,028,316 | 0 | 0 | Against |
| JPMorgan | 1,000,946 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 888,487 | 0 | 0 | 0 | For |
| State Street | 571,287 | 0 | 0 | 0 | For |
| Jackson National | 557,442 | 0 | 0 | 0 | For |
| TIAA | 539,348 | 0 | 0 | 0 | For |
| Charles Schwab | 442,624 | 0 | 0 | 0 | For |
| Equitable | 223,676 | 0 | 0 | 0 | For |
| First Trust | 219,863 | 0 | 0 | 0 | For |
| BNY Mellon | 14,353 | 192,350 | 0 | 0 | Mixed |
| OLD WESTBURY FUNDS INC | 194,004 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 192,539 | 0 | 0 | 0 | For |
| MassMutual | 189,127 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 174,015 | 0 | 0 | Against |
| John Hancock | 173,324 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 148,400 | 0 | 0 | 0 | For |
| Federated Hermes | 147,700 | 0 | 0 | 0 | For |
| Dimensional | 136,870 | 0 | 0 | 0 | For |
Fund voting reports, all 125 managers: 64,170,134 for, 1,560,913 against, 5,207 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 16,553,248 | 0 | 0 | 0 | For |
| Fidelity | 9,796,707 | 10,224 | 0 | 0 | For |
| Wellington | 6,981,073 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,394,932 | 115,403 | 0 | 0 | For |
| BlackRock | 4,466,521 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,540,790 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 3,136,845 | 0 | 0 | 0 | For |
| State Street | 2,765,595 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD & CO LTD | 2,426,931 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,987,575 | 0 | 0 | 0 | For |
| Man Group plc | 1,821,640 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 1,570,444 | 0 | 0 | 0 | For |
| JPMorgan | 1,534,457 | 0 | 0 | 0 | For |
| American Century | 0 | 1,123,799 | 0 | 0 | Against |
| Northern Trust | 730,992 | 2,751 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 686,264 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 0 | 617,424 | 0 | 0 | Against |
| Nuveen | 544,190 | 0 | 0 | 0 | For |
| UBS | 0 | 521,780 | 0 | 0 | Against |
| Charles Schwab | 501,586 | 0 | 0 | 0 | For |
| Desjardins Global Asset Management Inc. | 0 | 392,352 | 0 | 0 | Against |
| Amundi | 0 | 351,577 | 0 | 0 | Against |
| Newton Investment Management North America, LLC | 0 | 331,533 | 0 | 0 | Against |
| Mitsubishi UFJ Trust & Banking Corp | 317,350 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 311,441 | 0 | 0 | 0 | For |
Institutional-manager reports, all 408 managers: 75,649,679 for, 5,135,738 against, 1,433 not voted, 3 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2024.
ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2024”): 114,460,115 for, 3,456,326 against — passed, per its Form 8-K filed May 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2024.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 130 asset managers below reported 65,543,601 for, 223,603 against, 5,207 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 18,597,294 | 0 | 0 | 0 | For |
| Capital Group | 14,436,051 | 0 | 0 | 0 | For |
| Fidelity | 9,412,385 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,521,656 | 0 | 0 | 0 | For |
| BlackRock | 3,341,538 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,331,971 | 0 | 0 | 0 | For |
| Dodge & Cox | 2,854,341 | 0 | 0 | 0 | For |
| American Century | 1,028,316 | 0 | 0 | 0 | For |
| JPMorgan | 1,000,946 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 888,487 | 0 | 0 | 0 | For |
| State Street | 571,204 | 83 | 0 | 0 | For |
| Jackson National | 557,442 | 0 | 0 | 0 | For |
| TIAA | 539,348 | 0 | 0 | 0 | For |
| Charles Schwab | 442,624 | 0 | 0 | 0 | For |
| Equitable | 223,676 | 0 | 0 | 0 | For |
| First Trust | 219,863 | 0 | 0 | 0 | For |
| BNY Mellon | 206,703 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 194,004 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 192,539 | 0 | 0 | 0 | For |
| MassMutual | 189,127 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 174,015 | 0 | 0 | Against |
| John Hancock | 173,324 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 148,400 | 0 | 0 | 0 | For |
| Federated Hermes | 147,700 | 0 | 0 | 0 | For |
| Dimensional | 136,870 | 0 | 0 | 0 | For |
Showing the 25 largest of 130 asset managers. All 130 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 126,463,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 14.71% |
| 2 | Capital Group | 11.42% |
| 3 | Fidelity | 7.44% |
| 4 | T. Rowe Price | 3.58% |
| 5 | BlackRock | 2.64% |
| 6 | AMCAP FUND | 2.63% |
| 7 | Dodge & Cox | 2.26% |
| 8 | American Century | 0.81% |
| 9 | JPMorgan | 0.79% |
| 10 | NEW ECONOMY FUND | 0.70% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 13.09% |
| 2 | Fidelity | 7.75% |
| 3 | Wellington | 5.52% |
| 4 | T. Rowe Price | 5.15% |
| 5 | BlackRock | 3.53% |
| 6 | Dodge & Cox | 2.80% |
| 7 | Capital Research Global Investors | 2.48% |
| 8 | State Street | 2.19% |
| 9 | BAILLIE GIFFORD & CO LTD | 1.92% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.57% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 16,767,625 | 13.26% | Form 13F, quarter ended March 31, 2024 |
| Vanguard Group | 13,565,452 | 10.73% | Form 13F, quarter ended March 31, 2024 |
| BlackRock | 9,903,601 | 7.83% | Form 13F, quarter ended March 31, 2024 |
| Wellington Management | 7,209,005 | 5.70% | Form 13F, quarter ended March 31, 2024 |
| JPMorgan Chase | 4,543,770 | 3.59% | Form 13F, quarter ended March 31, 2024 |
| T. Rowe Price | 3,685,753 | 2.91% | Form 13F, quarter ended March 31, 2024 |
| Capital International | 3,651,217 | 2.89% | Form 13F, quarter ended March 31, 2024 |
| State Street | 3,191,373 | 2.52% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 2,001,718 | 1.58% | Form 13F, quarter ended March 31, 2024 |
| Norges Bank | 1,521,412 | 1.20% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 126,463,000 shares outstanding, as reported by ALNYLAM PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At ALNYLAM PHARMACEUTICALS INC.'s shareholder meeting held May 16, 2024, in the 2023-2024 proxy season, 503 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 3,855 separate fund positions. On the most widely held item on that ballot — To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive… — ALNYLAM PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ALNYLAM PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 20, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALNYLAM PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
ALNYLAM PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “ALNYLAM PHARMACEUTICALS (ALNY) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/alnylam-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.